Clinical Delivery of Therapeutic Agents Based on Metals by Fox, John
CLINICAL DELIVERY OF THERAPEUTIC AGENTS
BASED ON METALS
John Fox
Shire Pharmaceuticals PIc., Planning Department,
East Anton, Andover, SP10 5RG, UK
Abstract
Metals have been used in clinical practice for hundreds of years and for a variety of in(lications.
Although potent agents whose activity may be adapted by manipulation of their chemistry and that
of associated ligands, their use has been limited by toxic effects. There is now a burgeoning series,
of delivery technologies available which may be adapted to the administration of metal base d drug,.
Together with greater understanding of metal chemistry and their mechanisms of action in disea’se
processes, there is an opportunity to increase the use of metals in medicine by targeting their
action more effectively to the therapeutic site and/or protecting the body from toxic effects..
Introduction
Metals have been used in medicine for hundreds of years. Most common delivery methods were via
the oral route and topical application. Indications ranged from the treatment of syphilis witlt arsenic
or mercury to Chinese herbal remedies which contained lead, mercury and arsenic amon.c. others .
Populations have also been exposed to metals through their use in agriculture, for insta’nce the use
of mercury as a fungicide on seed corn which led to many deaths in the early 1980’s in Iraq when
food shortages led to the use of seed grain to make bread despite Government warni’ngs.
There are still many areas of clinical application where metals make a signific’.nt contribution.
Examples would include the use of platinum (cancer chemotherapy), mercury (rJental amalgams),
gold (Rheumatoid Arthritis), Silver (wound healing), Technetium (imaging), Ircn supplements) and
so on. A general theme evident in the use of metals in medicine throughout history is the balance
of efficacy with respect to the target biochemical system and the potential for immediate or long
term toxicity. This paper seeks to explore the delivery means that are cu’rently available or in
development that may assist in retaining activity at the target site while reducin g the toxicity of metal-
based therapeutics. Successful formulations would allow the potency of metalls to ..b,e deployed in a
much wider range of indications and at an earlier stage in those indications here use is currently
limited by toxicity.
Discussion
There are several issues which influence the use of metals in appropriate the;rapeutic areas. They
tend to have a high potency, but their effects may be relatively unspecific. The pharmacological
activity of metals is essentially a function of their chemistry but structure activity relationships may be
influenced by factors such as available ligands or oxidation state.
Toxicity may be acute, as in the cytotoxic nature of the cisplatinum compounds used as
chemotherapeutic agents in the treatment of some cancers,, or long term,. Lon.g term toicity
commonly arises due to accumulation over time as n the case of osteomalaca due to the
accumulation of aluminium by patients with end stage renal disease. TP,is toxicity potenti.d has
severe implications for the development of products which would receive a I/larketing Autho’dsation
from regulatory bodies. Regulatory Authorities look for clear demonstratior of quality, sa:(ety and
efficacy in Product Licence Applications. Assuming the quality of product is pprop,riate no simple
matter in a highly regulated manufacturing environment -a product is ap,provable only if it has
advantages in efficacy and/or safety over existing treatments, pharmaceutica,1 or otherwise. Cost is
not a basis for approval or rejection, although pricing will have an influence or, the extent of use of a
licensed product.
133Vol. 4, No. 3, 1997 Clinical Delivery ofTherapeutic Agents Based on Metals
The use of many metal based drugs is limited by their toxicity to severe diseases or other conditions
that are unresponsive to normal management regimens. In these cases the risk:benefit ratio
becomes acceptable because there are few or no alternative means of active treatment. This
indicates that the challenge faced by those developing new metal based drugs is to target the
active principle more effectively and/or to mask the toxic properties of the preparation until it
reaches its site of action.
There are many different routes of delivery of drugs to the body. These include:
Oral
Sub-cutaneous
Parenteral
Including implants/pumps
Transdermal
Patches, gels
Passive; Active (ie Iontophoresis)
Mucosal
Buccal, nasal, rectal, vaginal
Inhalation
Intrathecal
Intracapsular
Opthalmic
Strategies for the delivery of metals could involve the use of carrier molecules as targeting vehicles
or the masking of a potentially toxic moiety. Much work has been done on the use of biodegradable
polymers as transport agents and long-acting enzyme preparations have been developed using
polylactide-coglycolide (PLGA) and polyethylene glycol polymers.
Issues to be addressed for this type of formulation largely relate to the technical challenges
associated with combining the active agent with its carrier, delivery of the combination and
presentation of the metal in its active form at the target site. Since there may still be some systemic
exposure to the unprotected metal a risk of residual toxicity remains. The validity of such an
approach will depend on the target site to be reached, likely carriers and the chemistry of the metal
and potential ligands.
An alternative strategyis to encase the metal complex Within an external structure such as a
liposome, constructed of polar lipid molecules, or proteinoids, hollow microspheres of condensed
amino-acids. This strategy could enhance absorption, potentially reduce toxicity and protect the
active moiety from deactivation before it reached the target site. Wrapping technologies are able to
protect the active agent through the processes of absorption and distribution. They involve
embedding the drug within a matrix whose physicochemical properties can be adjusted to suit the
properties of the compound and the chosen delivery route. At present the only liposome-based
marketed products are indicated for systemic fungal and mycobacterium infections and for
dermatological use. However products are in development for use as cancer chemotherapeutic
agents.
An alternative means of protecting the active molecule could make use of a pro-drug approach,
whereby biochemical processes within the body modify the formulation to release the active form.
Again, challenges to be overcome would most likely arise from technical issues with respect to initial
manufacture of a reproducible formulation and consistent release of the therapeutic agent at the
site of action.
Several of the established routes of administration could be used for the above strategies. Oral
formulations represent the majority of novel drug .delivery systemsa and carrier based strategies are
available to increase the bioavailability of high molecular weight compounds or complexes. The use
of the oral route can provide opportunities to tailor the kinetics of the product, including the onset
time of drug release, or if appropriate the site of absorption within the gastrointestinal tract.
Inhalation technology is now able to deliver therapeutic levels of high molecular weight compounds
at low inspiration rates using propellant-free devices. The deep lung has a large surface area for
drug delivery and constitutes an opportunity for rapid delivery of compounds capable of being
formulated in dry powder form.
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Targeted delivery could include systems such as the use of viral vectors or monoclonal antibodies
to ensure the active agent is delivered preferentially to the target site in sufficient amounts while
reducing the potential for side effects. For products where continuous delivery is desirable a range
of implantable polymers, hydrogels and pumps are available. Novel polymers and ceramic particles
are under development as controlled release media for injectable products. For all these
technologies, consideration should be given to the advantage of the new delivery in clinical
practice which will involve comparison of the efficacy and safety profiles against accepted
treatments.
In summary, the challenge for the future development of metals in clinical practice is to improve
current means of delivery where metals are of known benefit, to identify additional therapeutic uses
of metals in medicine and to link potential uses of metals to enabling technologies. The recent
development of innovative means of delivery for pharmaceuticals of various molecular weights and
physiochemical characteristics has introduced an opportunity to expand the use of metals in
medicine. By imaginative construction of desired product profiles and close collaboration between
chemists, physicians and delivery technology specialists it will be feasible to construct formulations
that will make best use Of the potency of metals while improving their safety profile.
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